{"slug":"cancers-least-served","title":"Cancers with most trials per approved product","basis":"Cancers with at least ten trials, excluding umbrella records that other cancers name as their parent, ordered by trials divided by approved products, with cancers that have no approved product first.","metric":"Trials per approved product","context":"Trials and approved products","how":"For each cancer with ten or more trial records, divides the trial count by the number of products with status approved that list the cancer. Cancers with no approved product cannot be divided and are placed first, ordered by their trial count. The ten-trial floor keeps a cancer with one trial and no product from topping the table, and umbrella records (any cancer that another cancer record names as its parent) are left out because their approvals sit on the subtypes. Supportive care medicines (antiemetics, growth factors, epoetins, bone-modifying agents, antidotes, opioids for cancer pain, immunoglobulin; drug records flagged supportive) are not products or treatments here and are left out.","coverage":{"filled":5946,"of":5969,"what":"trials name at least one cancer","share":0.996},"total":73,"top":50,"rows":[{"rank":1,"id":"metastatic-cancer","name":"Metastatic cancer (cancer that has spread)","kind":"cancer","route":"/cancers/metastatic-cancer/","value":1000570,"metric":"no approved product","context":"570 trials, 0 approved products"},{"rank":2,"id":"colon-cancer","name":"Colon cancer (adenocarcinoma of the colon)","kind":"cancer","route":"/cancers/colon-cancer/","value":1000462,"metric":"no approved product","context":"462 trials, 0 approved products"},{"rank":3,"id":"borderline-resectable-pdac","name":"Borderline resectable pancreatic ductal adenocarcinoma","kind":"cancer","route":"/cancers/borderline-resectable-pdac/","value":1000038,"metric":"no approved product","context":"38 trials, 0 approved products"},{"rank":4,"id":"ampullary","name":"Ampullary cancer (ampulla of Vater)","kind":"cancer","route":"/cancers/ampullary/","value":1000021,"metric":"no approved product","context":"21 trials, 0 approved products"},{"rank":5,"id":"oesophageal-squamous-cell-carcinoma","name":"Oesophageal squamous cell carcinoma","kind":"cancer","route":"/cancers/oesophageal-squamous-cell-carcinoma/","value":1000017,"metric":"no approved product","context":"17 trials, 0 approved products"},{"rank":6,"id":"prostate-intermediate-risk","name":"Localised prostate cancer, intermediate risk","kind":"cancer","route":"/cancers/prostate-intermediate-risk/","value":1000016,"metric":"no approved product","context":"16 trials, 0 approved products"},{"rank":7,"id":"prostate-low-risk","name":"Localised prostate cancer, very low and low risk","kind":"cancer","route":"/cancers/prostate-low-risk/","value":1000014,"metric":"no approved product","context":"14 trials, 0 approved products"},{"rank":8,"id":"lung-squamous-cell-carcinoma","name":"Squamous cell carcinoma of the lung","kind":"cancer","route":"/cancers/lung-squamous-cell-carcinoma/","value":1000013,"metric":"no approved product","context":"13 trials, 0 approved products"},{"rank":9,"id":"hpv-positive-oropharyngeal-cancer","name":"HPV-positive oropharyngeal cancer","kind":"cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","value":1000011,"metric":"no approved product","context":"11 trials, 0 approved products"},{"rank":10,"id":"rectal-cancer","name":"Rectal cancer","kind":"cancer","route":"/cancers/rectal-cancer/","value":614,"metric":"614","context":"614 trials, 1 approved product"},{"rank":11,"id":"locally-advanced-pdac","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","kind":"cancer","route":"/cancers/locally-advanced-pdac/","value":111,"metric":"111","context":"111 trials, 1 approved product"},{"rank":12,"id":"extrahepatic-cholangiocarcinoma","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","kind":"cancer","route":"/cancers/extrahepatic-cholangiocarcinoma/","value":77,"metric":"77","context":"77 trials, 1 approved product"},{"rank":13,"id":"resectable-pdac","name":"Resectable pancreatic ductal adenocarcinoma","kind":"cancer","route":"/cancers/resectable-pdac/","value":50.5,"metric":"50.5","context":"101 trials, 2 approved products"},{"rank":14,"id":"metastatic-pdac","name":"Metastatic pancreatic ductal adenocarcinoma","kind":"cancer","route":"/cancers/metastatic-pdac/","value":49.8,"metric":"49.8","context":"249 trials, 5 approved products"},{"rank":15,"id":"prostate-high-risk","name":"Localised prostate cancer, high and very high risk","kind":"cancer","route":"/cancers/prostate-high-risk/","value":38,"metric":"38","context":"38 trials, 1 approved product"},{"rank":16,"id":"tnbc-early","name":"Early triple-negative breast cancer","kind":"cancer","route":"/cancers/tnbc-early/","value":27.5,"metric":"27.5","context":"165 trials, 6 approved products"},{"rank":17,"id":"muscle-invasive-bladder-cancer","name":"Muscle-invasive and advanced bladder cancer","kind":"cancer","route":"/cancers/muscle-invasive-bladder-cancer/","value":24.5,"metric":"24.5","context":"49 trials, 2 approved products"},{"rank":18,"id":"msi-high-colorectal","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","kind":"cancer","route":"/cancers/msi-high-colorectal/","value":21.5,"metric":"21.5","context":"86 trials, 4 approved products"},{"rank":19,"id":"intrahepatic-cholangiocarcinoma","name":"Intrahepatic cholangiocarcinoma","kind":"cancer","route":"/cancers/intrahepatic-cholangiocarcinoma/","value":21,"metric":"21","context":"84 trials, 4 approved products"},{"rank":20,"id":"prostate-bcr","name":"Biochemical recurrence of prostate cancer","kind":"cancer","route":"/cancers/prostate-bcr/","value":19,"metric":"19","context":"19 trials, 1 approved product"},{"rank":21,"id":"egfr-mutant-nsclc","name":"EGFR-mutated non-small-cell lung cancer","kind":"cancer","route":"/cancers/egfr-mutant-nsclc/","value":15.2,"metric":"15.2","context":"152 trials, 10 approved products"},{"rank":22,"id":"resectable-nsclc","name":"Resectable stage I to III non-small-cell lung cancer","kind":"cancer","route":"/cancers/resectable-nsclc/","value":15.125,"metric":"15.1","context":"121 trials, 8 approved products"},{"rank":23,"id":"her2-amplified-colorectal","name":"HER2-amplified colorectal cancer","kind":"cancer","route":"/cancers/her2-amplified-colorectal/","value":14,"metric":"14","context":"28 trials, 2 approved products"},{"rank":24,"id":"lung-adenocarcinoma","name":"Adenocarcinoma of the lung","kind":"cancer","route":"/cancers/lung-adenocarcinoma/","value":13,"metric":"13","context":"13 trials, 1 approved product"},{"rank":25,"id":"non-muscle-invasive-bladder-cancer","name":"Non-muscle-invasive bladder cancer","kind":"cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","value":12.333333333333334,"metric":"12.3","context":"37 trials, 3 approved products"},{"rank":26,"id":"stage-iii-unresectable-nsclc","name":"Unresectable stage III non-small-cell lung cancer","kind":"cancer","route":"/cancers/stage-iii-unresectable-nsclc/","value":12.333333333333334,"metric":"12.3","context":"37 trials, 3 approved products"},{"rank":27,"id":"tnbc-metastatic","name":"Metastatic triple-negative breast cancer","kind":"cancer","route":"/cancers/tnbc-metastatic/","value":11.846153846153847,"metric":"11.8","context":"154 trials, 13 approved products"},{"rank":28,"id":"platinum-resistant-ovarian-cancer","name":"Platinum-resistant ovarian cancer","kind":"cancer","route":"/cancers/platinum-resistant-ovarian-cancer/","value":11.666666666666666,"metric":"11.7","context":"35 trials, 3 approved products"},{"rank":29,"id":"gastric-her2-positive","name":"HER2-positive gastric cancer","kind":"cancer","route":"/cancers/gastric-her2-positive/","value":11,"metric":"11","context":"22 trials, 2 approved products"},{"rank":30,"id":"kras-g12c-nsclc","name":"KRAS G12C-mutant non-small-cell lung cancer","kind":"cancer","route":"/cancers/kras-g12c-nsclc/","value":10.5,"metric":"10.5","context":"42 trials, 4 approved products"},{"rank":31,"id":"prostate-mcrpc","name":"Metastatic castration-resistant prostate cancer","kind":"cancer","route":"/cancers/prostate-mcrpc/","value":10.3,"metric":"10.3","context":"103 trials, 10 approved products"},{"rank":32,"id":"recurrent-metastatic-hnscc","name":"Recurrent or metastatic head and neck squamous cell carcinoma","kind":"cancer","route":"/cancers/recurrent-metastatic-hnscc/","value":10.25,"metric":"10.3","context":"41 trials, 4 approved products"},{"rank":33,"id":"braf-v600e-colorectal","name":"BRAF V600E-mutant colorectal cancer","kind":"cancer","route":"/cancers/braf-v600e-colorectal/","value":10,"metric":"10","context":"20 trials, 2 approved products"},{"rank":34,"id":"extensive-stage-sclc","name":"Extensive-stage small-cell lung cancer","kind":"cancer","route":"/cancers/extensive-stage-sclc/","value":10,"metric":"10","context":"80 trials, 8 approved products"},{"rank":35,"id":"kras-g12c-colorectal","name":"KRAS G12C-mutant colorectal cancer","kind":"cancer","route":"/cancers/kras-g12c-colorectal/","value":9.5,"metric":"9.5","context":"19 trials, 2 approved products"},{"rank":36,"id":"uveal-melanoma","name":"Uveal melanoma","kind":"cancer","route":"/cancers/uveal-melanoma/","value":9.5,"metric":"9.5","context":"19 trials, 2 approved products"},{"rank":37,"id":"cll-relapsed","name":"Relapsed or refractory chronic lymphocytic leukaemia","kind":"cancer","route":"/cancers/cll-relapsed/","value":9.333333333333334,"metric":"9.3","context":"28 trials, 3 approved products"},{"rank":38,"id":"osteosarcoma","name":"Osteosarcoma","kind":"cancer","route":"/cancers/osteosarcoma/","value":9,"metric":"9","context":"18 trials, 2 approved products"},{"rank":39,"id":"myeloma-relapsed-refractory","name":"Relapsed or refractory multiple myeloma","kind":"cancer","route":"/cancers/myeloma-relapsed-refractory/","value":8.9,"metric":"8.9","context":"89 trials, 10 approved products"},{"rank":40,"id":"limited-stage-sclc","name":"Limited-stage small-cell lung cancer","kind":"cancer","route":"/cancers/limited-stage-sclc/","value":8,"metric":"8","context":"24 trials, 3 approved products"},{"rank":41,"id":"oesophageal-adenocarcinoma","name":"Oesophageal and junctional adenocarcinoma","kind":"cancer","route":"/cancers/oesophageal-adenocarcinoma/","value":8,"metric":"8","context":"16 trials, 2 approved products"},{"rank":42,"id":"mantle-cell-lymphoma","name":"Mantle cell lymphoma","kind":"cancer","route":"/cancers/mantle-cell-lymphoma/","value":7.6,"metric":"7.6","context":"38 trials, 5 approved products"},{"rank":43,"id":"advanced-recurrent-endometrial-cancer","name":"Advanced or recurrent endometrial cancer","kind":"cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/","value":7.333333333333333,"metric":"7.3","context":"22 trials, 3 approved products"},{"rank":44,"id":"recurrent-metastatic-cervical-cancer","name":"Recurrent or metastatic cervical cancer","kind":"cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/","value":7.333333333333333,"metric":"7.3","context":"22 trials, 3 approved products"},{"rank":45,"id":"her2-mutant-nsclc","name":"HER2-mutant non-small-cell lung cancer","kind":"cancer","route":"/cancers/her2-mutant-nsclc/","value":6.75,"metric":"6.8","context":"27 trials, 4 approved products"},{"rank":46,"id":"hcc-intermediate","name":"Intermediate hepatocellular carcinoma (BCLC B)","kind":"cancer","route":"/cancers/hcc-intermediate/","value":6.5,"metric":"6.5","context":"13 trials, 2 approved products"},{"rank":47,"id":"platinum-sensitive-ovarian-cancer","name":"Platinum-sensitive ovarian cancer","kind":"cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/","value":6.333333333333333,"metric":"6.3","context":"19 trials, 3 approved products"},{"rank":48,"id":"hcc-advanced","name":"Advanced hepatocellular carcinoma (BCLC C)","kind":"cancer","route":"/cancers/hcc-advanced/","value":6,"metric":"6","context":"48 trials, 8 approved products"},{"rank":49,"id":"her2-positive-early-breast-cancer","name":"Early HER2-positive breast cancer","kind":"cancer","route":"/cancers/her2-positive-early-breast-cancer/","value":5.75,"metric":"5.8","context":"23 trials, 4 approved products"},{"rank":50,"id":"cll-treatment-naive","name":"Chronic lymphocytic leukaemia, first treatment","kind":"cancer","route":"/cancers/cll-treatment-naive/","value":5.5,"metric":"5.5","context":"22 trials, 4 approved products"}]}